FIFTH WAIVER TO AGREEMENT AND PLAN OF MERGERWaiver to Agreement and Plan of Merger • October 28th, 2024 • Revance Therapeutics, Inc. • Pharmaceutical preparations
This FIFTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated October 25, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Company”), and waives certain provisions (as set forth herein) of that certain Agreement and Plan of Merger, dated August 11, 2024 (as the same may be amended, modified or restated in accordance with the terms thereof, the “Merger Agreement”), by and among Parent, Merger Sub and the Company. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Merger Agreement.
Sixth Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated October 24, 2024Exclusive Distribution Agreement • October 28th, 2024 • Revance Therapeutics, Inc. • Pharmaceutical preparations
EXCLUSIVE DISTRIBUTION AGREEMENTExclusive Distribution Agreement • October 28th, 2024 • Revance Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This EXCLUSIVE DISTRIBUTION AGREEMENT (this “Agreement”), dated as of October 24, 2024 (the “Effective Date”), is entered into by and between Revance Therapeutics, Inc., a Delaware corporation with its principal place of business at 1222 Demonbreun St., 20th Floor, Nashville, TN 37203 and Revance Australia Pty. Ltd., an Australia proprietary company with its principal place of business at 1222 Demonbreun St., 20th Floor, Nashville, TN 37203 (collectively, “Revance”), on the one hand and Teoxane SA, a company organized under the laws of Switzerland with its principal place of business at rue du Lyon 105, CH-1203, Geneva, Switzerland (“Teoxane”) on the other hand (each a “Party” and collectively, the “Parties”).
